NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
75907-0095-40 | 75907-0095 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Apr 15, 2024 | In Use | |
21695-0829-40 | 21695-0829 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Apr 11, 2008 | In Use | |
66530-0249-40 | 66530-0249 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Apr 11, 2008 | Aug 31, 2022 | No Longer Used |
21922-0041-12 | 21922-0041 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Nov 6, 2023 | In Use | |
54868-4554-01 | 54868-4554 | Imiquimod | Aldara | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Jun 19, 2003 | Sep 30, 2009 | No Longer Used | |
51672-4118-06 | 51672-4118 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Mar 17, 2017 | In Use | |
68682-0085-31 | 68682-0085 | Fluorouracil | Fluorouracil | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Sep 30, 1990 | Jan 31, 2010 | No Longer Used | |
00187-5525-60 | 00187-5525 | Bexarotene | Targretin | 1.0 g/100g | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Topical | Jun 28, 2000 | In Use | |
62935-0452-45 | 62935-0452 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 23, 2002 | Apr 26, 2019 | No Longer Used | ||
70383-0073-01 | 70383-0073 | MOTIXAFORTIDE ACETATE | Aphexda | 62.0 mg/1.7mL | Ancillary Therapy | Immunostimulant | Stem cell mobilizer | Subcutaneous | Sep 8, 2023 | In Use | |
62756-0452-36 | 62756-0452 | Octreotide acetate | BYNFEZIA Pen | 2.5 mg/mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Feb 24, 2025 | In Use | ||
00004-0357-30 | 00004-0357 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Mar 29, 2011 | Jun 30, 2024 | No Longer Used |
50242-0108-86 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 23, 2017 | In Use | |
62935-0453-45 | 62935-0453 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 7, 2005 | In Use | |||
15054-1090-04 | 15054-1090 | Lanreotide acetate | Somatuline Depot | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sep 1, 2019 | In Use | ||
69097-0907-67 | 69097-0907 | LANREOTIDE ACETATE | LANREOTIDE ACETATE | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | May 22, 2024 | In Use | ||
00004-0365-09 | 00004-0365 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Nov 1, 2011 | In Use | |
55150-0356-01 | 55150-0356 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Jul 24, 2023 | In Use | |
70720-0950-36 | 70720-0950 | Goserelin | ZOLADEX | 3.6 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | Mar 31, 2018 | In Use | ||
44206-0457-22 | 44206-0457 | Human Immunoglobulin G | Hizentra | 0.2 g/mL | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | Subcutaneous | Jan 1, 2020 | In Use | |
73491-0627-01 | 73491-0627 | Efbemalenograstim alfa-vuxw | RYZNEUTA | 20.0 mg/mL | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 23, 2023 | In Use | |
00069-0291-10 | 00069-0291 | filgrastim-aafi | Nivestym | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sep 24, 2018 | In Use | |
58468-0140-01 | 58468-0140 | Plerixafor | Mozobil | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Dec 15, 2008 | Mar 23, 2018 | No Longer Used |
00069-2522-02 | 00069-2522 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
63539-0252-02 | 63539-0252 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use |
Found 11564 results — Export these results